Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Our trainees’ stories are in the media!
Visit the Pittsburgh Post-Gazette to dive into publications written by past trainees! Kraynak, T. E. (2023, December 3). How your brain ages, and some ways … Pittsburgh...
